Theramix developed a new imaging technology for sensitively detection of cell death. This is the technology that currently guides our drug discovery and development. Since diseases involve cellular damages, we can use this imaging approach to monitor progression of diseases, to screen drugs that repair tissues, and to evaluate efficacy and toxicity of drugs. MEDSen probe is designed for imaging cell death in small animals. It detects dying cells, that is, the real time changes caused by drugs are monitored. It's a powerful tool for preclinical testing of drugs, which save us from tedious animal experiments, biochemical and pathological analysis as needed in the traditional drug development process. We are also developing new probes for clinical investigations based on this new technology platform.
We want to share MEDSen probe with pharmaceuticals to accelerate their drug development. It provides quicker, cheaper and more accurate preclinical drug testing in terms of efficacy, toxicity, dose optimization, and surrogate endpoint evaluation.
Nude mice were intravenously injected with MEDSen probes. Images were recorded before and 2 hours after intravenously injection of endotoxin (LPS, 2 mg/kg) that induced lung injury.
